Artennua is an optimized version of Artemisia annua – a medicinal plant used for centuries in Chinese Medicine and is the source of artemisinin, the molecule recommended by the WHO to treat malaria. Artemisinin, its derivatives, and other secondary metabolites have the potential to treat many other afflictions; however, Artemisia annua produces very low quantities of artemisinin and thus global supply is limited. At Sequentia we are scientists and social entrepreneurs; we have used natural plant biopharming methods to improve the characteristics of the Artemisia annua plant so that its benefits can be exploited.
Innovation and agriculture, medicinal plants and biotechnology, this is Tricopharming. Using biological techniques we stimulate the natural capacity of the plants trichomes to be molecules factory. A well done article titled “Biopharmaceutical Agriculture, from the laboratory to the field”, Newspaper La Vanguardia tells our story: our company, our first product and our plans for the…
Sequentia Biotech has created Biotech Tricopharming Research as a spin-out to commercialise Artennua, an optimized version of Artemisia annua, and the first product to derive from their agropharma R&D department. Sequentia was able to quintuplicate the annual production of the plant, triplicate the foliar biomass and duplicate the concentration of artemisinin in the lab. This…
We are delighted to share with you our new naming, new image and new web! Over the last year, our Artepharming project has gathered momentum, objectives have been met and milestones have been achieved...
